Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial Comparing Seltorexant (MIN-202) Versus Quetiapine as Adjunctive Therapy to Antidepressants in Patients With Major Depressive Disorder
21. Dezember 2017 08:00 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Dec. 21, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) in Patients With Insomnia Disorder
06. Dezember 2017 08:30 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Dec. 06, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) as Adjunctive Therapy in Patients With Major Depressive Disorder
05. September 2017 08:00 ET
|
Minerva Neurosciences, Inc.
WALTHAM, Mass., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Announces European Commission Approval of Amendment of MIN-202 Agreement With Janssen
25. August 2017 08:30 ET
|
Minerva Neurosciences, Inc.
Proceeds from amended agreement, combined with finances raised from recent public stock offering and current financial resources, significantly extend Minerva cash runway Combined proceeds are...
Minerva Announces Amended Agreement for MIN-202 in Insomnia
31. Mai 2017 16:05 ET
|
Minerva Neurosciences, Inc.
Minerva to gain global strategic control over development of MIN-202 for insomnia Janssen cash payments to Minerva of up to $70 million, including $30 million upfront All shares in Minerva held by...
Minerva Neurosciences Reports Fiscal 2016 Fourth Quarter and Year End Financial Results and Business Updates
13. März 2017 07:30 ET
|
Minerva Neurosciences, Inc.
Multiple positive data readouts during 2016 provide foundation for initiation of advanced clinical trials with three product candidates in 2017 Management to host conference call today at...
Minerva Neurosciences Reports Third Quarter 2016 Financial Results and Business Updates
03. November 2016 07:30 ET
|
Minerva Neurosciences, Inc.
WALTHAM, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Reports Second Quarter 2016 Financial Results and Business Updates
04. August 2016 07:30 ET
|
Minerva Neurosciences, Inc.
Positive clinical data advance development with MIN-101 in schizophrenia and MIN-117 in major depressive disorder Additional trials also planned with MIN-202 in insomnia disorder and major...
Minerva Neurosciences Announces Positive Top Line Results From Phase Ib Clinical Trial in Major Depressive Disorder With MIN-202
11. März 2016 08:30 ET
|
Minerva Neurosciences, Inc
Treatment with selective orexin-2 receptor antagonist observed to be well tolerated and to improve symptoms of depression, independent from its effect on sleep WALTHAM, Mass., March 11, 2016 ...